Deutsche Bank set a $18.00 target price on Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) in a research report sent to investors on Sunday morning. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

A number of other analysts also recently weighed in on VRX. BidaskClub downgraded shares of Valeant Pharmaceuticals International from a hold rating to a sell rating in a research report on Sunday, August 6th. Piper Jaffray Companies set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a sell rating in a research report on Wednesday, August 9th. HC Wainwright set a $17.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a research report on Wednesday, August 9th. Scotiabank upped their target price on shares of Valeant Pharmaceuticals International from $14.00 to $16.00 and gave the stock a sector perform rating in a research report on Wednesday, August 9th. Finally, Mizuho reaffirmed an underperform rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a research report on Wednesday, August 9th. Five equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of Hold and a consensus target price of $17.46.

Shares of Valeant Pharmaceuticals International (NYSE VRX) opened at $17.75 on Friday. The firm has a market cap of $6,150.00, a PE ratio of 2.80, a PEG ratio of 0.47 and a beta of -0.22. The company has a debt-to-equity ratio of 4.84, a current ratio of 1.26 and a quick ratio of 1.03. Valeant Pharmaceuticals International has a 1 year low of $8.31 and a 1 year high of $18.25.

In other news, Director John Paulson purchased 344,216 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were bought at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the purchase, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.87% of the company’s stock.

A number of institutional investors have recently made changes to their positions in VRX. Moors & Cabot Inc. lifted its stake in Valeant Pharmaceuticals International by 55.0% during the 3rd quarter. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company’s stock valued at $337,000 after acquiring an additional 8,400 shares during the period. Janney Montgomery Scott LLC lifted its stake in Valeant Pharmaceuticals International by 33.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 20,095 shares of the specialty pharmaceutical company’s stock valued at $288,000 after acquiring an additional 5,069 shares during the period. Cubist Systematic Strategies LLC lifted its stake in Valeant Pharmaceuticals International by 9,253.2% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 56,119 shares of the specialty pharmaceutical company’s stock valued at $804,000 after acquiring an additional 55,519 shares during the period. AMP Capital Investors Ltd lifted its stake in Valeant Pharmaceuticals International by 6.3% during the 3rd quarter. AMP Capital Investors Ltd now owns 142,910 shares of the specialty pharmaceutical company’s stock valued at $2,043,000 after acquiring an additional 8,484 shares during the period. Finally, Stifel Financial Corp lifted its stake in Valeant Pharmaceuticals International by 18.4% during the 3rd quarter. Stifel Financial Corp now owns 236,576 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after acquiring an additional 36,705 shares during the period. Institutional investors own 49.49% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Deutsche Bank Analysts Give Valeant Pharmaceuticals International (VRX) a $18.00 Price Target” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/12/06/deutsche-bank-analysts-give-valeant-pharmaceuticals-international-vrx-a-18-00-price-target.html.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.